Get the Stockscreener App
85.33
0.09%
0.08
After Hours:
85.33
Edwards Lifesciences Corp stock is traded at $85.33, with a volume of 2.38M.
It is up +0.09% in the last 24 hours and up +0.73% over the past month.
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
See More
Previous Close:
$85.25
Open:
$85.46
24h Volume:
2.38M
Relative Volume:
0.60
Market Cap:
$49.52B
Revenue:
$5.88B
Net Income/Loss:
$1.34B
P/E Ratio:
36.33
EPS:
2.3489
Net Cash Flow:
$799.60M
1W Performance:
-1.75%
1M Performance:
+0.73%
6M Performance:
+10.79%
1Y Performance:
+17.55%
1-Day Range:
$84.08
$85.48
1-Week Range:
$84.08
$87.44
52-Week Range:
$65.94
$87.89
Edwards Lifesciences Corp Stock (EW) Company Profile
Name
Edwards Lifesciences Corp
Sector
Industry
Phone
(949) 250-2500
Address
ONE EDWARDS WAY, IRVINE, CA
Compare EW with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EW
Edwards Lifesciences Corp
|
85.33 | 49.47B | 5.88B | 1.34B | 799.60M | 2.3489 |
|
ABT
Abbott Laboratories
|
124.19 | 217.86B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
94.71 | 141.35B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
348.18 | 134.41B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
96.05 | 123.15B | 34.76B | 4.79B | 5.21B | 3.7017 |
Edwards Lifesciences Corp Stock (EW) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-18-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Nov-03-25 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-29-25 | Upgrade | Jefferies | Hold → Buy |
| Oct-29-25 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Oct-08-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-07-25 | Upgrade | Evercore ISI | In-line → Outperform |
| Jul-29-25 | Upgrade | BTIG Research | Neutral → Buy |
| Apr-24-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-30-25 | Upgrade | Stifel | Hold → Buy |
| Jan-16-25 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Dec-16-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-11-24 | Resumed | Morgan Stanley | Equal-Weight |
| Sep-18-24 | Downgrade | Jefferies | Buy → Hold |
| Jul-31-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Jul-29-24 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jul-25-24 | Downgrade | BofA Securities | Buy → Neutral |
| Jul-25-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-25-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jul-25-24 | Downgrade | TD Cowen | Buy → Hold |
| Jul-25-24 | Downgrade | Truist | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| May-22-24 | Upgrade | Citigroup | Neutral → Buy |
| May-14-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Mar-07-24 | Upgrade | BofA Securities | Neutral → Buy |
| Feb-02-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-04-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-11-23 | Downgrade | Citigroup | Buy → Neutral |
| Nov-28-23 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Sep-26-23 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-19-23 | Initiated | Robert W. Baird | Outperform |
| May-30-23 | Resumed | Morgan Stanley | Overweight |
| Mar-29-23 | Initiated | UBS | Neutral |
| Mar-08-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-06-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jan-31-23 | Downgrade | Bernstein | Outperform → Underperform |
| Jan-30-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-06-22 | Downgrade | Stifel | Buy → Hold |
| Oct-28-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-26-22 | Initiated | Mizuho | Buy |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Jul-29-22 | Downgrade | Canaccord Genuity | Buy → Hold |
| Apr-13-22 | Initiated | Truist | Buy |
| Apr-06-22 | Initiated | Wolfe Research | Outperform |
| Mar-16-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Mar-02-22 | Resumed | BofA Securities | Neutral |
| Feb-02-22 | Upgrade | UBS | Neutral → Buy |
| Jan-27-22 | Reiterated | Citigroup | Buy |
| Jan-27-22 | Reiterated | Evercore ISI | Outperform |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | Stifel | Buy |
| Jan-27-22 | Reiterated | UBS | Neutral |
| Dec-17-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-15-21 | Upgrade | Citigroup | Neutral → Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Dec-06-21 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jul-30-21 | Reiterated | Canaccord Genuity | Buy |
| Jul-30-21 | Reiterated | Deutsche Bank | Hold |
| Jul-30-21 | Reiterated | Jefferies | Buy |
| Jul-30-21 | Reiterated | Morgan Stanley | Overweight |
| Jul-30-21 | Reiterated | Oppenheimer | Outperform |
| Jul-30-21 | Reiterated | Stifel | Buy |
| Jul-30-21 | Reiterated | UBS | Neutral |
| Jul-30-21 | Reiterated | Wells Fargo | Equal Weight |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Apr-05-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-16-20 | Downgrade | Citigroup | Buy → Neutral |
| Dec-11-20 | Reiterated | Canaccord Genuity | Buy |
| Sep-11-20 | Initiated | Wolfe Research | Underperform |
| Apr-28-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-17-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-10-20 | Initiated | Oppenheimer | Outperform |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-24-19 | Reiterated | Canaccord Genuity | Buy |
| Sep-23-19 | Initiated | Piper Jaffray | Overweight |
| Jul-24-19 | Reiterated | BofA/Merrill | Buy |
| Mar-18-19 | Reiterated | Canaccord Genuity | Buy |
| Jan-18-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jan-03-19 | Initiated | Deutsche Bank | Hold |
| Nov-28-18 | Initiated | UBS | Neutral |
| Oct-16-18 | Initiated | Barclays | Underweight |
| Oct-02-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Oct-02-18 | Downgrade | Guggenheim | Buy → Neutral |
View All
Edwards Lifesciences Corp Stock (EW) Latest News
Edwards Lifesciences (NYSE:EW) Will Want To Turn Around Its Return Trends - simplywall.st
Econ Financial Services Corp Acquires 15,836 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Ninety One UK Ltd Buys 969,030 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Ninety One North America Inc. Acquires 71,017 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences Corporation (NYSE:EW) Short Interest Down 19.2% in December - MarketBeat
VIRGINIA RETIREMENT SYSTEMS ET Al Purchases 56,000 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Cwm LLC Purchases 43,065 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences (NYSE:EW) Shares Unloaded Rep. Josh Gottheimer - MarketBeat
Mirova US LLC Has $219.47 Million Position in Edwards Lifesciences Corporation $EW - MarketBeat
Farmers & Merchants Investments Inc. Sells 15,037 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Stifel Upgrades Edwards Lifesciences (EW) - MSN
Edwards Lifesciences Corp Stock Price Live, Charts & News - The Economic Times
Edwards Sapien M3 Valve Gets FDA Approval - Orange County Business Journal
World Investment Advisors Has $2.81 Million Stake in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences Corporation $EW Shares Sold by Litman Gregory Wealth Management LLC - MarketBeat
Edwards Lifesciences Corp (EW) Stock Price History & Data - Traders Union
Covea Finance Takes Position in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences Corporation (NYSE:EW) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
How Do Investors Really Feel About Edwards Lifesciences Corp? - Sahm
Transcatheter Mitral Valve Replacement System Receives FDA Clearance - Diagnostic and Interventional Cardiology
HALPER SADEH LLC ENCOURAGES EDWARDS LIFESCIENCES CORPORATION SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS - Finviz
Edwards Lifesciences Corp (EW) Stock Price, Trades & News - GuruFocus
Edwards Lifesciences Corporation $EW Shares Sold by OLD National Bancorp IN - MarketBeat
FDA Approves Edwards Lifesciences' SAPIEN M3 Mitral Valve Replacement System as First Transseptal Transcatheter Therapy - BioSpace
Edwards Lifesciences (EW): Assessing Valuation After Recent Share Price Strength - Yahoo Finance
EW SEC FilingsEdwards Lifesciences Corp 10-K, 10-Q, 8-K Forms - Stock Titan
Edwards lands first FDA approval for transcatheter MVR - BioWorld MedTech
The Zacks Analyst Blog Highlights Cardinal Health, Medtronic, Intuitive Surgical and Edwards Lifesciences - Yahoo Finance
Edwards Lifesciences Says FDA Approves Valve Replacement System - marketscreener.com
Edwards wins FDA approval for Sapien M3 mitral valve, marking first transseptal transcatheter therapy - MassDevice
Edwards Lifesciences’ SAPIEN M3 becomes first FDA-approved mitral valve system - Investing.com
Edwards Lifesciences gets FDA approval for SAPIEN M3 mitral valve system By Investing.com - Investing.com South Africa
Edwards Lifesciences gets FDA approval for SAPIEN M3 mitral valve system - Investing.com Canada
FDA approves Edwards Lifesciences' Sapien M3 mitral valve replacement system as first transseptal transcatheter therapy - marketscreener.com
FDA Approves Edwards Lifesciences' SAPIEN M3 Mitral Valve Replacement System as First Transseptal Transcatheter Therapy – Company AnnouncementFT.com - Financial Times
OFI Invest Asset Management Raises Stock Holdings in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences Corporation $EW Shares Sold by Legacy Wealth Asset Management LLC - MarketBeat
Edwards Lifesciences Corp. stock outperforms competitors on strong trading day - MarketWatch
Edwards Lifesciences Advances Smart Surgery Monitoring With Completed SMART TRENDS Study - TipRanks
Seilern Investment Management Ltd Sells 183,101 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
How JP Morgan’s Upgrade and 2026 Conference Spotlight Will Impact Edwards Lifesciences (EW) Investors - simplywall.st
Edwards Lifesciences (BSP:E1WL34) EV-to-OCF : 46.58 (As of Dec. 20, 2025) - GuruFocus
Edwards Lifesciences Corporation $EW Shares Sold by Texas Permanent School Fund Corp - MarketBeat
Profit Review: How Edwards Lifesciences Corporation stock compares to industry benchmarksPrice Action & Capital Efficiency Focused Ideas - Улправда
Edwards Lifesciences Corporation (EW) Stock Price | Live Quotes & Charts | NYSE - StocksToTrade
How Edwards Lifesciences Corporation stock performs in rate cut cyclesJuly 2025 Setups & Daily Profit Focused Stock Screening - Улправда
What makes Edwards Lifesciences Corporation stock attractive to growth fundsJuly 2025 Opening Moves & Community Verified Trade Alerts - ulpravda.ru
Edwards Lifesciences (WBO:EWLS) EV-to-OCF : 44.69 (As of Dec. 19, 2025) - GuruFocus
Edwards Lifesciences (NYSE:EW) Updates FY 2025 Earnings Guidance - MarketBeat
Amiral Gestion Has $21.99 Million Position in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences completes key study on SAPIEN XT THV - MSN
Edwards Lifesciences Corp Stock (EW) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
0.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):